CN107531780B - 抗-Rho GTPase的构象单域抗体及其用途 - Google Patents

抗-Rho GTPase的构象单域抗体及其用途 Download PDF

Info

Publication number
CN107531780B
CN107531780B CN201680007071.1A CN201680007071A CN107531780B CN 107531780 B CN107531780 B CN 107531780B CN 201680007071 A CN201680007071 A CN 201680007071A CN 107531780 B CN107531780 B CN 107531780B
Authority
CN
China
Prior art keywords
ser
gly
ala
thr
single domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680007071.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107531780A (zh
Inventor
奥雷利安·奥利雄
劳拉·凯勒
吉勒斯·法夫尔
尼古拉斯·贝里
帕特里克·希纳斯特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT CLAUDIUS REGAUD
Universite de Toulouse
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT CLAUDIUS REGAUD
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, INSTITUT CLAUDIUS REGAUD, Universite Toulouse III Paul Sabatier filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN202111282155.5A priority Critical patent/CN114133450B/zh
Publication of CN107531780A publication Critical patent/CN107531780A/zh
Application granted granted Critical
Publication of CN107531780B publication Critical patent/CN107531780B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
CN201680007071.1A 2015-02-03 2016-02-02 抗-Rho GTPase的构象单域抗体及其用途 Expired - Fee Related CN107531780B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111282155.5A CN114133450B (zh) 2015-02-03 2016-02-02 抗-Rho GTPase的构象单域抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305160 2015-02-03
EP15305160.2 2015-02-03
PCT/EP2016/052136 WO2016124568A1 (en) 2015-02-03 2016-02-02 Anti-rho gtpase conformational single domain antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111282155.5A Division CN114133450B (zh) 2015-02-03 2016-02-02 抗-Rho GTPase的构象单域抗体及其用途

Publications (2)

Publication Number Publication Date
CN107531780A CN107531780A (zh) 2018-01-02
CN107531780B true CN107531780B (zh) 2021-11-02

Family

ID=52464303

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680007071.1A Expired - Fee Related CN107531780B (zh) 2015-02-03 2016-02-02 抗-Rho GTPase的构象单域抗体及其用途
CN202111282155.5A Expired - Fee Related CN114133450B (zh) 2015-02-03 2016-02-02 抗-Rho GTPase的构象单域抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111282155.5A Expired - Fee Related CN114133450B (zh) 2015-02-03 2016-02-02 抗-Rho GTPase的构象单域抗体及其用途

Country Status (5)

Country Link
US (3) US10544210B2 (https=)
EP (1) EP3253791A1 (https=)
JP (3) JP6871866B2 (https=)
CN (2) CN107531780B (https=)
WO (1) WO2016124568A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
US20220275534A1 (en) * 2018-10-17 2022-09-01 The University Of Tokyo Peptide Library Production Method
WO2020219407A1 (en) * 2019-04-22 2020-10-29 University Of Washington Chemically induced protein dimerization systems
EP3986453A1 (en) * 2019-06-20 2022-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- protease nexin-1 conformational single domain antibodies and uses thereof
WO2021078359A1 (en) * 2019-10-21 2021-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of cubilin for the treatment of chronic kidney diseases
GB202005876D0 (en) * 2020-04-22 2020-06-03 Univ Dundee Protein degradation
CN114736302B (zh) * 2022-05-12 2022-10-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞无血清培养基
CN114605554B (zh) * 2022-05-12 2022-07-05 诺赛联合(北京)生物医学科技有限公司 一种间充质干细胞培养基

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538600A (ja) * 2006-05-12 2009-11-12 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 癌治療の標的としてのｄｕｂ３
WO2014195713A1 (en) * 2013-06-06 2014-12-11 David J Rowlands Single domain antibody display

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
CN102399288B (zh) * 2011-10-19 2013-06-05 山西德丰信成生物科技有限公司 针对免疫球蛋白Fc段的单域重链抗体
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538600A (ja) * 2006-05-12 2009-11-12 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 癌治療の標的としてのｄｕｂ３
WO2014195713A1 (en) * 2013-06-06 2014-12-11 David J Rowlands Single domain antibody display

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Biotechnological applications of recombinant single-domain antibody fragments";Ario de Marco 等;《Microbial Cell Factories》;20110609;第10卷;第1-14页 *
"Chain A, Nanobody/vhh Domain Ega1，PDB：4KARN_A";Schmitz,K.R. 等;《Genbank》;20130828;第1-2页 *
"Generation of a Single Chain Antibody Variable Fragment (scFv) to Sense Selectively RhoB Activation";Patrick Chinestra 等;《PLOS ONE》;20141103;第9卷(第11期);第1-11页 *
"Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection";Marine Goffinet 等;《BMC Biotechnology》;20080331;第8卷(第34期);第1-14页 *
"Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation";Tomoyuki Tanaka 等;《The EMBO Journal》;20031231;第22卷(第5期);第1025-1035页 *
"Use of Phage Display for the Identification of Molecular Sensors Specific for Activated Rho";Patrick Chinestra 等;《Methods in Molecular Biology》;20121231;第827卷;第283-303页 *

Also Published As

Publication number Publication date
CN114133450B (zh) 2023-09-22
JP2018506302A (ja) 2018-03-08
US20180022794A1 (en) 2018-01-25
JP2020156498A (ja) 2020-10-01
US10544210B2 (en) 2020-01-28
CN107531780A (zh) 2018-01-02
EP3253791A1 (en) 2017-12-13
WO2016124568A1 (en) 2016-08-11
JP2022130514A (ja) 2022-09-06
US20220213221A1 (en) 2022-07-07
CN114133450A (zh) 2022-03-04
JP7095019B2 (ja) 2022-07-04
US20210171658A1 (en) 2021-06-10
US11319381B2 (en) 2022-05-03
JP6871866B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
CN107531780B (zh) 抗-Rho GTPase的构象单域抗体及其用途
JP6905492B2 (ja) ニューロピリン１：セマフォリン軸を介した、制御性ｔ細胞の安定性および機能の制御に基づく療法
KR20210050535A (ko) 항-bcma 단일 도메인 항체 및 그 적용
CN103180340A (zh) 细胞内免疫
CN107249636B (zh) 以ckap4作为靶分子的抗肿瘤剂
EP2941486A1 (en) Intracellular phenotypic screening
AU2018204243B2 (en) Single chain intrabodies that alter huntingtin mutant degradation
JP7162897B2 (ja) 融合タンパク質
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
US11999776B2 (en) IGFR-like 2 receptor and uses thereof
KR20230107628A (ko) Wnt 수용체 ryk에 대한 항체 변이체
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
KR101620812B1 (ko) CLC-Kb 염화 이온 채널 조절물질 도출을 위한 세포기반 형광 이미징 고효율 검색 및 광범위 특성 연구용 세포주
Li et al. NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection
RU2812207C2 (ru) Способы и фармацевтические композиции для лечения заболеваний, связанных с тубулин карбоксипептидазами (tcp)
KR20120087057A (ko) ｐ５３β를 발현하는 세포주 및 이의 생산 방법
Cegarra et al. Search and Characterization of ITM2A as a New Potential Target for Brain Delivery
KR101254243B1 (ko) ｃｈｋ１ 단백질 및 ＨＪＵＲＰ 단백질 간의 상호작용을 억제하는 펩티드, 이를 포함하는 항암제 및 항암제를 스크리닝하는 방법
Rizk et al. LUBAC PUB domain interactions restrict Met1-linked ubiquitination to prevent embryonic lethality and immune pathology
KR20200088683A (ko) 세포질 침투성이 증진된 항체의 스크리닝 방법
HK1185353A (zh) 细胞内免疫
WO2015110707A1 (en) Methods and uses related to adamts3
WO2005014809A1 (ja) 肝臓ガン特異的ポリペプチド、該ポリペプチドをコードするポリヌクレオチド、及び該ポリペプチドの発現を抑制するｒｎａ分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211102